Drug Profile
JNJ 90009530
Alternative Names: Anti-CD20 CART cells; Anti-CD20 CART-transduced T cells - AbelZeta Pharma; Anti-CD20 chimeric antigen receptor T cell therapy - AbelZeta Pharma; C-CAR066; CAR-CD20 T cell therapy; CAR066; CAR066 CAR; CART20; CBM-C20.1; CBM-CD20 1; Genetically engineered lymphocyte therapy - AbelZeta Pharma; JNJ-90009530Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Chinese PLA General Hospital
- Developer AbelZeta Pharma; Chinese PLA General Hospital; Institute of Hematology & Blood Diseases Hospital; Janssen Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II B-cell lymphoma; Leukaemia
- Phase I Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 14 Dec 2023 AbelZeta receives IND approval from USFDA for JNJ 90009530 for diffuse large B-cell lymphoma
- 12 Dec 2023 Pooled efficacy and adverse events data from phase I trials in non-Hodgkin's lymphoma released by AbelZeta Pharma
- 09 Dec 2023 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)